Viveve Medical's U CAN-CER VIVE Foundation Funds Groundbreaking Cancer Research Collaboration
- The U CAN-CER VIVE Foundation provided a $459,010 grant to enhance cancer clinical trials at Karmanos Cancer Institute.
- The TheraBionic P1 device, approved by the FDA, targets cancer cells and shows promise in liver cancer treatment.
- Karmanos Cancer Institute and U CAN-CER VIVE Foundation collaborate to improve cancer treatment and patient outcomes through innovative research.
Innovative Collaboration Boosts Cancer Research Efforts
The Barbara Ann Karmanos Cancer Institute recently secures a significant grant of $459,010 from the U CAN-CER VIVE Foundation, aimed at enhancing clinical trials for numerous cancer types, including breast, colorectal, and pancreatic cancers. This funding marks a pivotal advancement in cancer treatment research, enabling scientists and oncologists at Karmanos to explore innovative therapies that may improve patient outcomes. With this grant, the institute reaffirms its commitment to leading-edge research and its status as a National Cancer Institute-Designated Comprehensive Cancer Center.
Central to this initiative is the ongoing investigation into the TheraBionic P1 device, which received FDA approval in November 2023. This groundbreaking portable treatment utilizes radiofrequency electromagnetic fields to target cancer cells, particularly in patients with advanced hepatocellular carcinoma (HCC), the most common form of liver cancer. Early clinical results indicate that the TheraBionic P1 device can facilitate tumor shrinkage, inhibit the proliferation of new cancer cells, and enhance survival rates in patients. The innovative approach represents a culmination of over two decades of research, marking a transformative moment in the treatment landscape for liver cancer.
Dr. Anthony Shields, a medical oncologist and associate center director at Karmanos, emphasizes the importance of the partnership with the U CAN-CER VIVE Foundation, co-founded by Ryan and Kelley LaFontaine. He expresses gratitude for their support, which underscores a shared dedication to advancing cancer treatment through innovative research. The collaboration not only strengthens the Karmanos Cancer Institute's research capabilities but also highlights a mutual commitment to improving the quality of life for patients facing daunting cancer diagnoses.
In addition to the focus on liver cancer, the funding will bolster clinical trials for a variety of other cancers, thereby broadening the scope of research initiatives at Karmanos. This comprehensive approach ensures that multiple cancer types receive attention, paving the way for potential breakthroughs across various treatment modalities. The U CAN-CER VIVE Foundation's support exemplifies how partnerships can catalyze significant advancements in cancer research, ultimately benefiting patients and their families during their most challenging times.
The Karmanos Cancer Institute continues to be at the forefront of cancer research, fostering collaborations that enhance their clinical trials and treatment options. Together with the U CAN-CER VIVE Foundation, they strive to create a future where innovative therapies provide hope and improved outcomes for cancer patients.